Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer

In Vivo

Volumn 17, Issue 2, 2003, Pages 153-156

  Kong, Beihua ^a   Wang, Wenxia ^a   Liu, Chunsheng ^a   Song, Li ^a   Ma, Daoxin ^a   Qu, Xun ^a   Jiang, Jie ^a   Yang, Xingsheng ^a   Zhang, Youzhong ^a   Wang, Bo ^a   Wei, Ming Q ^b   Yang, Qifeng ^a,c  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

GCV; Lentivirus; Ovarian cancer; Suicide gene; VP22

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; GANCICLOVIR; LENTIVIRUS VECTOR; MUCIN 1; MUCIN 1 ANTIBODY; SINGLE CHAIN VARIABLE REGION FRAGMENT VP22 HERPES SIMPLEX VIRUS TYPE 1 THYMIDINE KINASE; UNCLASSIFIED DRUG; VP22 HERPES SIMPLEX VIRUS TYPE 1 THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; LENTIVIRINAE; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; OVARY CARCINOMA; SUICIDE GENE THERAPY; SURVIVAL TIME;

EID: 0037870271     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Teneriello MG and Park RC: Early detection of ovarian cancer. CA Cancer J Clin 45: 71-87, 1995.
2. Mattews T and Boehme R: Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 10: s490-s494, 1998.
3. Culver KW, Ram Z, Walbridge S, Ishii H, Oldfield EH and Blaese RM: In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992.
4. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL and Abraham GN: The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-5283, 1993.
5. Rosenfeld ME, Feng M, Michael SI, Siegal GP, Alvarez RD and Curiel DT: Adenoviral-mediated delivery of the Herpes Simplex Virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin Cancer Res 1: 1571-1580, 1995.
6. Sciortino MT, Taddeo B, Poon APW, Mastino A and Roizman B: Of the three tegument proteins that package mRNA in herpes simplex virions, one (VP22) transports the mRNA to uninfected cells for expression prior to viral infection. Proc Nat Acad Sci 99; 8318-8328, 2002.
7. Dilber MS, Phelan A, Aints A, Mohamed AJ, Elliott G, Smith CI and O'Hare P: Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 6: 12-21, 1999.
8. Liu CS, Kong B, Xia HH, Ellem KA and Wei M: VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death. J Gene Med 3: 145-152, 2001.
9. Frankel AD and Pabo CO: Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 1189-1193, 1988.
10. Lai Z, Han I, Zirzow G, Brady RO and Reiser J: Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors. Proc Nat Acad Sci 97: 11297-11302, 2000.
11. Descamps V, Duffour MT, Mathieu MC, Ferbabdez N, Cordier L, Abina MA, Kremer E, Perricaudet M and Haddada H: Strategies for cancer gene therapy using adenoviral vectors. J Mol Med 74: 183-189, 1996.
12. Koyama F, Sawada H, Hirao T, Fujii H, Hamada H and Nakano H: Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of Escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-flurorocytosine. Cancer Gene Ther 7: 1015-1022, 2000.
13. Xiang J, Chen Y and Moyana T: Combination immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer. Cancer Gene Ther 7: 1023-1033, 2000.
14. Huber BE, Richards CA and Krenitsky TA: Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc Nat Acad Sci 88: 8039-8043, 1991.
15. Kasahara N, Dozy AM and Kan YW: Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266: 1373-1376, 1994.
16. Giuntoli RL II, Rodriguez GC, Whitaker RS, Dodge R and Voynow JA: Mucin gene expression in ovarian cancers. Cancer Res 58: 5546-5550, 1998.
17. Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB, Arafat W, Hughes JV, Siegal GP and Curiel DT: Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2: 524-530, 2000.
18. Hasenburg A, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Kieback CC, Kaplan A, Kaufman RH, Ramzy I, Aguilar-Cordova E and Kieback DG: Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 7: 839-844, 2000.
19. Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W, Arani RB, Johnson MR, Roberts BL, Siegal GP and Curiel DT: A cancer gene therapy approach utilizing an anti-erbB-2 single chain antibody-encoding adenovirus (AD21): A phase I trial. Clin Cancer Res 6: 3081-3087, 2000.
20. Buller RE, Shahin MS, Karlan B, Horowitz J, Mahavni V, Patrauskas S et al.: Multi-dose intraperitoneal Rad/p53 (SCH58500) gene replacement combined with chemotherapy in heavily pretreated recurrent ovarian cancer is associated with prolonged survival. Proc ASCO 20: 262a, 2001.
21. Muller CY, Coleman RL, Rogers P, Merritt JA, Parker K and Miller DS: Phase I intraperitoneal p53 gene transfer in ovarian cancer. Proc ASCO 20: 257a, 2001.